Bayer AG (OTCMKTS:BAYRY) has received a consensus recommendation of “Hold” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company.
BAYRY has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Bayer from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 23rd. JPMorgan Chase & Co. downgraded shares of Bayer from an “overweight” rating to a “neutral” rating in a research note on Wednesday, January 2nd. Finally, ValuEngine upgraded shares of Bayer from a “strong sell” rating to a “sell” rating in a research note on Monday, February 4th.
OTCMKTS:BAYRY traded up $0.15 during mid-day trading on Wednesday, reaching $19.28. 242,871 shares of the company’s stock were exchanged, compared to its average volume of 537,833. Bayer has a one year low of $16.58 and a one year high of $32.80. The firm has a market cap of $71.90 billion, a price-to-earnings ratio of 10.14, a P/E/G ratio of 1.28 and a beta of 0.96. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.04 and a current ratio of 1.59.
Bayer (OTCMKTS:BAYRY) last released its earnings results on Tuesday, November 13th. The company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.06). Bayer had a net margin of 15.58% and a return on equity of 13.59%. The firm had revenue of $11.52 billion during the quarter, compared to the consensus estimate of $11.31 billion. Sell-side analysts anticipate that Bayer will post 1.64 EPS for the current year.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Ex-Dividend
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.